Cargando…

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function

Therapeutic targeting of inhibitory checkpoint molecules in combination with chimeric antigen receptor (CAR) T cells is currently investigated in a variety of clinical studies for treatment of hematologic and solid malignancies. However, the impact of co-inhibitory axes and their therapeutic implica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blaeschke, Franziska, Ortner, Eva, Stenger, Dana, Mahdawi, Jasmin, Apfelbeck, Antonia, Habjan, Nicola, Weißer, Tanja, Kaeuferle, Theresa, Willier, Semjon, Kobold, Sebastian, Feuchtinger, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018974/ https://www.ncbi.nlm.nih.gov/pubmed/35464394 http://dx.doi.org/10.3389/fimmu.2022.845499

Ejemplares similares

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation
por: Kaeuferle, Theresa, et al.
Publicado: (2019)

Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells
por: Willier, Semjon, et al.
Publicado: (2020)

Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells
por: Kaeuferle, Theresa, et al.
Publicado: (2022)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
por: Willier, Semjon, et al.
Publicado: (2019)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
por: Cordes, Nicole, et al.
Publicado: (2021)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3ζ Phosphorylation
por: Rohrs, Jennifer A., et al.
Publicado: (2020)

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway
por: Tomkowicz, Brian, et al.
Publicado: (2015)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
por: Meng, Xianhui, et al.
Publicado: (2020)

Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3
por: Rapoport, Bernardo L., et al.
Publicado: (2023)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017)

The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4(+) T cells
por: Jacob, Rajesh Abraham, et al.
Publicado: (2021)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020)

The Binding Properties of Glycosylated and Non-Glycosylated Tim-3 Molecules on CD4(+)CD25(+) T Cells
por: Lee, Mi Jin, et al.
Publicado: (2009)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

P1366: SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMA
por: Reville, Patrick, et al.
Publicado: (2023)

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report
por: Funk, Christopher Ronald, et al.
Publicado: (2018)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
por: Maurer, Mark F., et al.
Publicado: (2022)

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
por: Rataj, Felicitas, et al.
Publicado: (2018)

CD3(+)CD8(+)CD28(−) T Lymphocytes in Patients with Lupus Nephritis
por: Żabińska, Marcelina, et al.
Publicado: (2016)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
por: Lesch, Stefanie, et al.
Publicado: (2022)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

The Role of CD28 and CD8(+) T Cells in Keloid Development
por: Shan, Mengjie, et al.
Publicado: (2022)

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2021)

Decreased CD8(+)CD28(+)/CD8(+)CD28(–) T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease
por: Dai, Shi-xue, et al.
Publicado: (2017)

CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance
por: Wu, Ling, et al.
Publicado: (2023)

Restoration of CD28 Expression in CD28(−) CD8(+) Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production
por: Topp, Max S., et al.
Publicado: (2003)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d8ub01h58v3j7ta5i7r6lqcroa